DT-101 not checked

Draig Therapeutics Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Major Depressive Disorder (MDD) (2 trials)
Main trialPhase 2
“In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.”In the company’s words, NCT07610473 on ClinicalTrials.gov

Other drugs for Major Depressive Disorder (MDD)

All 36 drugs for Major Depressive Disorder (MDD)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting May 2027 A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Phase 2Recruiting Aug 2027 A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow DT-101

Following is part of Solo: you see every change to DT-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in